Under the Page	Superior Reduction Act of	1995, no persons form 1449.	are required to respond to a collection of information of AVPTO		nplete if Known
FEB	<i>&/</i>		TION DISCLOSURE NT BY APPLICANT only sheets as necessary)	Application Number	10/663,265
	EMARINA	•	•	Filing Date	September 16, 2003
				First Named Inventor	Edith Mathiowitz
İ				Group Art Unit	1633
	•			Examiner Name	Maria Gomez Leavitt
Sheet	1	of	6	Attorney Docket Number	BU MAT1993-04fDIV3CON2

				U.S. PATENT DOCU	MENTS	
Examiner Cite Initials No. 1		US Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code 2 (if known)			
ML		4,272,398		Jaffe	06-09-1981	
1		4,775,624		Bang, et al.	10-04-1988	
		4,861,627		Mathiowitz, et al.	08-29-1989	
		4,863,735		Kohn, et al.	09-05-1989	
			Eppstein, et al. 01-30-1990			
		4,898,734		Mathiowitz, et al.	02-06-1990	
		5,100,669		Hyon, et al.	03-31-1992	
		5,100,792	_	Sanford, et al.	03-31-1992	
		5,171,217		March, et al.	12-15-1992	
		5,271,961		Mathiwitx, et al.	12-21-1992	
		5,366,881		Singh, et al.	11-22-1994	
	5			Grinstaff, et al.	06-17-1997	
		5,643,578		Robinson, et al.	07-01-1997	
		5,674,192		Sahatjian, et al.	10-07-1997	
V		5,763,416		Banadio, et al.	06-09-1998	

				F	OREIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1		Foreign Patent Doc	cument		Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	18
		Office.	Number ⁴	Kind Code ⁵ (if known)]		- gerot pp	
		EP	0-248-531		Southern Research Institute	12 -09-1987		
		EP	0.330 180		Biomaterials Universe, Inc.	08- 30-1989		
		EP.	0 302 582		Southern Research Institute	02-08-1989		
		EP	5 79347		Ferring Arzneimittel, GMBH-	01-19-1994		
		PCT_	WO 93/0885		Massachusetts Institute o Technology	05-123-1993		

	Α		
Examiner's Signature	Maria	deavitt	Date Considered 63 - 20 - 06
	/		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

					TODA BOTTOM TO THE STATE OF THE
Under the Pap	enwork Reduction Act o	f 1995, no persons	sare required to respond to a collection of information o	tess il contains a vatid OMB control number	
	Substitute for	form 1449	A/PTO	Соп	plete if Known
	STA	ATEME	TION DISCLOSURE NT BY APPLICANT iny sheets as necessary)	Application Number	10/663,265
		(,,	Filing Date	September 16, 2003
				First Named Inventor	Edith Mathiowitz
				Group Art Unit	1633
				Examiner Name	Maria Gomez Leavitt
Sheet	2	of	6 .	Attorney Docket Number	BU MAT1993-04fDIV3CON2

			U.S. PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	US Patent Docum	ent Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
_		Number Kind C (if kr	ode ² nown)			
ML		5,783,567	Hedley, et al.	07-21-1998		
		5,792,751	Ledley, et al.	08-11-1998		
		5,820,883	Tice, et al.	10-13-1998		
V		5,880,103	Urban, et al.	03-09-1999		
					· · · · · · · · · · · · · · · · · · ·	
		 	· · · · · · · · · · · · · · · · · · ·		······	

				F	OREIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.'		Foreign Patent Docu	ment		Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
		Office.3	Number ⁴	Kind Code ⁵ (if known)	5			
		PCT	WO 93/21906		Brown University Research Foundation	11-11-199 3		
		PGT	WO 93/25221		Alkermes Controlled Therapeutics	12-23 199 3		
ML		PCT	WO 94/23699		Medisorb Technologies International LP	10-27-1994		
		PCT_	WO 94/23738		Medisorb Technologies International LP	10-27-19 94		

Examiner's Signature	eavit "	Date Considered	3-20-06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type	a ptus	sign (+	inside t	his box →
-------------	--------	---------	----------	-----------

PTO/SB03A (10-96 Approved for use through 10/31/99. ONIB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute fo	r form 14	149A	PTO	. Complete if Known			
•	ATEN	IEN	ION DISCLOSURE IT BY APPLICANT y sheets as necessary)	Application Number	10/663,265		
	•			Filing Date	September 16, 2003		
•				First Named Inventor	Edith Mathlowitz		
				Group Art Unit	1633		
•				Examiner Name	Maria Gomez Leavitt		
3	of	\neg	6	Attorney Docket Number	BU MAT1993-04fDIV3CON2		

	·	OTHER ART - NON PATENT LITERATURE DOCUMENTS								
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T'							
		ACSADI, et al., "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs", Nature, 352(6338):815-8 (1991).								
		BENITA, et al., "Characterization of drug-loaded poly(d,I lactide) microspheres", J Pharm Sci., 73(12):1721-4 (1984).								
		BLAU, "Muscular dystrophy. Muscling in on gene therapy", Nature, 364(6439):673-5 (1993).								
		CHANGBEN and SHOUYUAN, "Use of human erythrocyte ghosts for transfer of 125I-BSA and 125I-DNA into animal cella hrough cell fusion", Scientia Sinica, XXV(8):860-865 (1982).								
		COGHLAN, et al., "Gene dream fades away" New Sci., 148(2005):14-5 (1995).								
		COHEN, "Naked DNA points way to vaccines", Science, 259(5102):1691-2 (1993).								
		CLARK, "Overview and general considerations of wound repair", in The Molecular and Cellular Biology of Wound Repair eds. R Clarkand P Henson, pp 3-33 1988.								
		CRYSTAL, "Transfer of genes to humans: early lessons and obstacles to success" Science, 270(5235):404-10 (1995).								
		DAGANI, "Gene therapy advance, anti-HIV antibodies work inside cell", Chemical & Engineering News, pp 3-4 (1993).								
		DUNCAN, "Drug-polymer conjugates: potential for improved chemotherapy", Anticancer Drugs, 3(3):175-210 (1992).								
		EISENBERG and CROTHERS, (eds) *Physical Chemistry with Application to the Life-Sciences*, Benjamin/Cummings Publishing CO., Mento Park, CA, p705, 1979.	_							

	_0					
Examiner's Signature	 Maria	deavitt	Date	e Considered	03-20-06	
	 		·			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial inference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

ㅗ	
т	

45-4-4-0	annual Darkurtina Art o	1 1005 <i>m</i> nemnm	is are required to respond to a collection of Information o	redonna brotoco ALAO biscu e anistraco di anaba	
Under the Pap	Substitute for				nplete if Known
	STA	ATEME	TION DISCLOSURE NT BY APPLICANT any sheets as necessary)	Application Number	10/663,265
				Filing Date	September 16, 2003
				First Named Inventor	Edith Mathiowitz
	_			Group Art Unit	1633
İ				Examiner Name	Maria Gomez Leavitt
Sheet	4	of	6	Attorney Docket Number	BU MAT1993-04fDIV3CON2

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		EtSENBRAUN, et al., "Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization", DNA Cell Biol., 12(9):791-7 (1993).	-
		FYNAN, et al. "DNA vaccines: protective immunizations by parenteral, musesal, and gene-gun inoculations" Proc Natl Acad Sci U S A., 90(24):11478-82 (1993).	<u></u>
		HAWLEY-NELSON, et al., "Lipofectamine reagent: A new higher efficiency polycationic liposome transfection reagent", Focus, 15:73-8 (1993).	
		HENSYL, et al. (eds) "Stedman's Medical Diotionary", 25th edition, Williams and Wilkins, Baltimore, MD. P 1473, 1990.	
		JIAQ, et al., "Persistence of plasmid DNA and expression in rat brain cells in vive", Exp. Neuml., 115(3):400-13 (1992).	
		KAY, et al., "In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs", Science, 262(5130):117-9 (1993).	
		LEDLEY, "Nonviral gene therapy: the promise of genes as pharmaceutical products", Hum Gene Ther., 6(9):1129-44 (1995).	
		LIM, et al., "Microencapsulation of living cells and tissues", J Pharm Sci., 70(4):351-4 (1981).	
		MARX, "A first step toward gene therapy for hemophilia B?", Science, 262(5130):29-30 (1993).	
		MATHIOWITZ, et al., "Polyanhydride microspheres. IV. Morphology ad characterization of systems made by spray drying", J. Appl Polymer Sci., 45:125-34 (1992).	
		MATHIOWITZ, et al., "Morphology of polyanhydride microsphere delivery systems", Scanning Microsc., 4(2):329-40 (1990).	

	 0					
Examiner's Signature	Maric	deavi	-	Date Considered	03-20-06	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type as	rks sign (+) inside	this box →
----------------	---------------------	------------

PTO/S8/08A (10:98 Approved for use through 10/31/99, OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		Con	nplete if Known		
	;	ATEME	TION DISCLOSURE NT BY APPLICANT any sheets as necessary)	Application Number	10/663,265
		(455 45		Filing Date	September 16, 2003
				First Named Inventor	Edith Mathlowitz
				Group Art Unit	1633
				Examiner Name	Maria Gomez Leavitt
\neg	5	of	6	Attorney Docket Number	BU MAT1993-04fDIV3CON2

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		MATHIOWITZ, et al. "Polyanhydride microspheres II. Microencapsulation by solvent removal", J. Appl Polymer Sci., 35:755- (1988).	
		MATHIOWITZ, et al., "Polyanhydride microspheres I. Hot-melt microencapsulation", J. Controlled Release, 5:13-22 (1987).	
-		MATHIOWITZ, et al., "Novel Microcapsules for delivery systems", Reactive Polymers, 6:275-83 (1987).	
		MULLIGAN, "The basic science of gene therapy", Science, 260(5110):926-32 (1993).	
		NABEL. et al. "Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans", <i>Proc Natl Acad Sci U S A.</i> , 90(23):11307-11 (1993).	
		NICOLAU, et al., "In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I", Proc Natl Acad Sci U S A., 80(4):1068-72 (1983).	
		PARTRIDGE, "Gene therapy. Muscle transfection made easy" Nature, (6338):757-8 (1991).	
_		ROSENBERG, et al., "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report", N Engl J Med., 319(25):1676-80 (T988).	
•		SALIB, et al., "Utilization of sodium alginate in drug microencapsulation", Pharmazeutisch Industrie, 40(11A):1230-34 (1978).	
		SAWHNEY, et al., "Bioerodible hydrogels based on phtopolymerized poly(ethyleneglycol)-co-poly(α-hydroxy acid) discrylate macromers", Macromolocules, 26:581-7 (1993).	
		TAI, et al., "Microencapsulation of recombinant cells: a new delivery system for gene therapy", FASEB J., 7(11):1061-9 (1993).	

		<i>II</i>			
Examiner's Signature	/	mana	deavit	Date Considered	03-20-06
	7				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a	ptus sign (+) inside	this box →

•	PTO/SB/08A (10-95
	Approved for use through 10/31/99. QMB 0651-0031
Patent and Tra	demark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO			A/PTO	Соп	nplete if Known
		ATEME	TION DISCLOSURE NT BY APPLICANT Inty sheets as necessary)	Application Number	10/663,265
		(000 00		Filing Date	September 16, 2003
			•	First Named Inventor	Edith Mathiowitz
				Group Art Unit	1633
			•	Examiner Name	Maria Gomez Leavitt
et	6	of	6	Attorney Docket Number	BU MAT1993-04fDIV3CON2

		OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner's Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
		ULMER, et al. "Heterologous protection against influenza by injection of DNA encoding a viral protein", Science, 259(5102):1745-9 (1993).						
	_	VERMA and SOMIA, "Gene therapy promises, problems and prospects" Nature, 389(6648):239-42 (1997).						
		Wil_SON, "Cystic fibrosis. Vehicles for gene therapy" Nature, 365(6448):691-2-(1993).						
		WIVEL, et al., "Germ-line gene modification and disease prevention: some medical and ethical perspectives", Science, 262(5133):533-8 (1993).						
		WOLFF, et al. "Direct gene transfer into mouse muscle in vivo" Science, 247(4949 Pt 1):1465-8 (1990).						
		YANG, "Gene transfer into mammalian somatic cells in vivo", Gritical Revies in Biotechnology, 12(4):335-356 (1992).						

	7		
Examiner's Signature	Mavic	deavitt	Date Considered 03-20-06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

^{*}EXAMINER: Injust if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.